Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

ERIBULINA BAXTER 0,44 MG/ML SOLUCION INYECTABLE EFG - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/ERIBULINA BAXTER 0,44 MG/ML SOLUCION INYECTABLE EFG

Approved

STANDARD

ERIBULINA BAXTER 0,44 MG/ML SOLUCION INYECTABLE EFG

Baxter Holding B.V.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Jul 15, 2024
Approval ID: 898419d66273d580
Company: Baxter Holding B.V.
Type: Standard

Approval Details

Approval Id: 898419d66273d580
Drug Cima Aemps Name: ERIBULINA BAXTER 0,44 MG/ML SOLUCION INYECTABLE EFG
Register Number: 1241819001
Holder Company Name: Baxter Holding B.V.
Marketing Company Name: Baxter S.L.
Holder Company Detail Path: /organization/baxter-holding-bv
Authorization Date: 2024-07-15
Dosage Form: SOLUCIÓN INYECTABLE
Dose: 0,44 mg/ml
Route Of Administration: VÍA INTRAVENOSA
Prescription Type: Uso Hospitalario
Commercialized: Yes
Company Name: Baxter Holding B.V.
Company Detail Path: /organization/baxter-holding-bv

Company Information

Pharmaceutical Company Name: Baxter Holding BV
Country Name: Netherlands

Active Ingredients

ERIBULINA MESILATO

1 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Jul 15, 2024

Approval ID

898419d66273d580

Type

Standard

Back to CIMA-AEMPS Approvals